Moody National Bank Trust Division Reduces Holdings in Eli Lilly and Company (NYSE:LLY)

Moody National Bank Trust Division decreased its position in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 11.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 32,953 shares of the company’s stock after selling 4,134 shares during the quarter. Eli Lilly and makes up about 0.3% of Moody National Bank Trust Division’s holdings, making the stock its 12th largest position. Moody National Bank Trust Division’s holdings in Eli Lilly and were worth $9,436,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of LLY. Icapital Wealth LLC purchased a new position in shares of Eli Lilly and during the first quarter worth about $28,000. AllSquare Wealth Management LLC purchased a new stake in Eli Lilly and in the 4th quarter valued at approximately $28,000. HWG Holdings LP purchased a new stake in Eli Lilly and in the 4th quarter valued at approximately $28,000. Leverty Financial Group LLC purchased a new stake in Eli Lilly and in the 4th quarter valued at approximately $29,000. Finally, FSB Premier Wealth Management Inc. acquired a new stake in shares of Eli Lilly and during the 4th quarter valued at approximately $30,000. 82.75% of the stock is currently owned by institutional investors.

NYSE:LLY traded up $4.66 during midday trading on Wednesday, reaching $302.00. 27,802 shares of the company traded hands, compared to its average volume of 2,976,611. Eli Lilly and Company has a twelve month low of $217.00 and a twelve month high of $324.08. The firm has a market capitalization of $286.95 billion, a price-to-earnings ratio of 44.05, a price-to-earnings-growth ratio of 2.02 and a beta of 0.40. The company has a debt-to-equity ratio of 1.60, a current ratio of 1.27 and a quick ratio of 0.98. The company has a fifty day moving average price of $297.40 and a 200 day moving average price of $274.74.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.32 by $0.30. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The company had revenue of $7.81 billion during the quarter, compared to analyst estimates of $7.29 billion. During the same quarter in the previous year, the firm posted $1.87 EPS. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. On average, equities research analysts forecast that Eli Lilly and Company will post 8.27 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Monday, May 16th were issued a $0.98 dividend. The ex-dividend date of this dividend was Friday, May 13th. This represents a $3.92 annualized dividend and a dividend yield of 1.30%. Eli Lilly and’s dividend payout ratio (DPR) is 58.07%.

Several brokerages have weighed in on LLY. Daiwa Capital Markets began coverage on Eli Lilly and in a report on Thursday, March 10th. They issued an “outperform” rating and a $286.00 price target for the company. Wells Fargo & Company boosted their price target on Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. StockNews.com downgraded Eli Lilly and from a “strong-buy” rating to a “buy” rating in a report on Monday, June 13th. SVB Leerink assumed coverage on Eli Lilly and in a report on Monday, May 23rd. They issued an “outperform” rating and a $341.00 price objective on the stock. Finally, Morgan Stanley raised their price objective on Eli Lilly and from $364.00 to $369.00 in a report on Friday, April 29th. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $311.00.

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total value of $313,440.00. Following the transaction, the chief accounting officer now owns 6,274 shares of the company’s stock, valued at approximately $1,966,522.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 2,500 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, March 30th. The stock was sold at an average price of $292.03, for a total transaction of $730,075.00. The disclosure for this sale can be found here. Insiders have sold 848,630 shares of company stock valued at $259,239,945 in the last ninety days. Company insiders own 0.12% of the company’s stock.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.